Antibody-Drug Conjugates in Gynecological Cancer: Review of the Clinical Data

摘要

In the first of this 2-part article published on October 1, 2022, Kathleen Moore, MD, summarized the current treatment landscape for gynecologic cancers and introduced the antibody-drug conjugates (ADCs) being testing to join this space. In this article, Moore reviews ongoing clinical trials for ADCs targeting folate receptor a (FRalpha), a sodium-dependent phosphate transporter (NaPi2b), HER2, and the potential impact of ADCs on patient care.